Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:03:11.444Z.
Calculation as of: 2026-10-06T15:03:11.444Z.
Quote observation: 2026-10-06T14:58:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8a37bf5da35164cf1f35689d787409f81d347c26e3158920307b7793dc95150d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$59.23M
PS Ratio
N/A
TTM Avg
11308.43
3Y Avg
6194.66
5Y Avg
6194.66
Market Cap
$57.74M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | $59.51M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $59.23M | N/A | 11308.43 | 6194.66 | 6194.66 |
| Oncolytics Biotech Inc. (ONCY)vs › | $58.96M | N/A | 253.07 | 189.95 | 270.31 |
| Adicet Bio, Inc. (ACET)vs › | $60.30M | N/A | 16.03 | 122.62 | 125.37 |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.74M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $61.60M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.18M | N/A | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.78M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $56.10M | N/A | 4.74 | 4.40 | 4.40 |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
